Peposertib and Radiation Therapy for Glioblastoma/Gliosarcoma
Phase 1
29
about 7.3 years
18+
1 site in TX
What this study is about
This trial is testing the safety and best dose of Peposertib, combined with radiation therapy, in treating patients with newly diagnosed MGMT unmethylated glioblastoma or gliosarcoma. The treatment involves using high-energy x-rays to kill tumor cells and shrink tumors. Peposertib may further stop tumor cell growth by blocking enzymes needed for cell division. Chemotherapy drugs like temozolomide are also used to stop tumor cell growth.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Radiation Therapy
- 2.Take Peposertib
- 3.Take Temozolomide
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
temozolomide
injection, intravenous
Primary: Maximum tolerated dose (MTD) (Stage I)
Secondary: Dose-limiting toxicities (DLT) (Stage I), Median overall survival (Stage I), Median overall survival (Stage II), Median progression-free survival (Stage I), Median progression-free survival (Stage II), Overall response rate (Stage I), Overall response rate (Stage II)
radiation, surgery
Oncology